Aarkstore -Female Hypoactive Sexual Desire Disorder-Pipeline Insights, 2014 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Aarkstore -Female Hypoactive Sexual Desire Disorder-Pipeline Insights, 2014

Description:

DelveInsights, Female Hypoactive Sexual Desire Disorder-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Female Hypoactive Sexual Desire Disorder. – PowerPoint PPT presentation

Number of Views:21

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore -Female Hypoactive Sexual Desire Disorder-Pipeline Insights, 2014


1
Female Hypoactive Sexual Desire Disorder-Pipeline
Insights, 2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/healthcare/77061/-female-
    hypoactive-sexual-desire-disorder-pipeline-insight
    s-2014

2
Summary
  • DelveInsights, Female Hypoactive Sexual Desire
    Disorder-Pipeline Insights, 2014, report provides
    comprehensive insights about pipeline drugs
    across this indication. A key objective of the
    report is to establish the understanding for all
    the pipeline drugs that fall under Female
    Hypoactive Sexual Desire Disorder. This report
    provides information on the therapeutic
    development based on the Female Hypoactive Sexual
    Desire Disorder dealing with all the pipeline
    drugs, comparative analysis at various stages
    covering Filed, Phase III, Phase II, Phase I, IND
    filed, Preclinical, Discovery and unknown stages,
    therapeutics assessment by monotherapy and
    combination products and molecule type drug
    information. The report also covers the companies
    information involved in the therapeutic
    development of the products. It also has
    highlighted the discontinued and dormant products.

3
Summary
  • Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts.Secondary
    sources information and data has been collected
    from various printable and non-printable sources
    like search engines, News websites, Government
    Websites, Trade Journals, White papers,
    Magazines, Trade associations, Books, Industry
    Portals, Industry Associations and access to
    available databases.Note This report requires
    certain updates. We have all the information
    available but require 3 business days to complete
    the process and ensure it is as up-to-date as
    possible. Certain sections in the report may be
    removed or altered based on the availability and
    relevance of data for the indicated Indication.

4
Summary
  • Scope 
  • The report provides a snapshot of the global
    therapeutic landscape of Female Hypoactive Sexual
    Desire DisorderThe report provides pipeline
    products under drug profile section which
    includes product description, MOA, licensors
    collaborators, development partner and chemical
    informationCoverage of the Female Hypoactive
    Sexual Desire Disorder pipeline on the basis of
    target, MOA, route of administration, technology
    involved and molecule typeThe report reviews key
    players involved in the therapeutics development
    for Female Hypoactive Sexual Desire Disorder and
    also provide company profilingThe report also
    gives the information of dormant and discontinued
    pipeline projects Pipeline products coverage
    based on various stages of development ranging
    from preregistration till discovery and
    undisclosed stages Provides pipeline assessment
    by monotherapy and combination therapy products,
    stage of development and molecule type

5
Summary
  • Reasons to buyComplete Pipeline intelligence
    and complete understanding over therapeutics
    development for Female Hypoactive Sexual Desire
    Disorder
  • Identify the relationship between the drugs and
    use it for target finding, drug repurposing, and
    precision medicine.
  • Devise corrective measures for pipeline projects
    by understanding Female Hypoactive Sexual Desire
    Disorder pipeline depth and focus of Indication
    therapeutics
  • Developing strategic initiatives to support your
    drug development activities.
  • Optimize your portfolio and keep you in touch
    with the rapidly changing pharmaceutical markets,
    and make the best decisions for your business.

6
Summary
  • Develop and design in licensing and out licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope
  • Provides strategically significant competitor
    information, analysis, and insights to formulate
    effective RD development strategies
  • Modify the therapeutic portfolio by identifying
    discontinued projects and understanding the
    factors that drove them from pipeline
  • Gaining a Full Picture of the Competitive
    Landscape for Evidence based Decisions

7
Table of Content
  • Female Hypoactive Sexual Desire Disorder
    OverviewFemale Hypoactive Sexual Desire Disorder
    Pipeline TherapeuticsFemale Hypoactive Sexual
    Desire Disorder Therapeutics under Development by
    Companies Female Hypoactive Sexual Desire
    Disorder Late Stage Products (Filed and Phase
    III)Comparative Analysis Female Hypoactive
    Sexual Desire Disorder Mid Clinical Stage
    Products (Phase II)Comparative Analysis Female
    Hypoactive Sexual Desire Disorder Early Clinical
    Stage Products (Phase I and IND
    Filed)Comparative Analysis Female Hypoactive
    Sexual Desire Disorder Discovery and Pre-Clinical
    Stage Products Comparative Analysis Drug
    Candidate Profiles

8
Table of Content
  • Female Hypoactive Sexual Desire Disorder
    Therapeutics Assessment Assessment by
    Monotherapy Products Assessment by Combination
    Products Assessment by Route of
    Administration Assessment by Molecule
    Type Female Hypoactive Sexual Desire Disorder
    Discontinued Products Female Hypoactive Sexual
    Desire Disorder Dormant ProductsCompanies
    Involved in Therapeutics Development for Female
    Hypoactive Sexual Desire Disorder Appendix Metho
    dology Contact Us Disclaimer

9
List of Tables
  • Number of Products under Development for Female
    Hypoactive Sexual Desire Disorder, 2014Number of
    Products under Development by Companies Comparati
    ve Analysis by Late Clinical Stage Products
    (Filed and Phase III), 2014Comparative Analysis
    Mid Clinical Stage Products (Phase II),
    2014Comparative Analysis Early Clinical Stage
    Products (Phase I and IND Filed),
    2014Comparative Analysis Discovery and
    Pre-Clinical Stage Products, 2014Drug Candidates
    ProfilesFemale Hypoactive Sexual Desire Disorder
    Assessment by Monotherapy Products Female
    Hypoactive Sexual Desire Disorder Assessment by
    Combination Products 

10
List of Tables
  • Female Hypoactive Sexual Desire Disorder
    Assessment by Route of Administration Female
    Hypoactive Sexual Desire Disorder Assessment by
    Stage and Route of Administration Female
    Hypoactive Sexual Desire Disorder Assessment by
    Molecule Type Female Hypoactive Sexual Desire
    Disorder Assessment by Stage and Molecule
    Type Female Hypoactive Sexual Desire Disorder
    Therapeutics Discontinued Products Female
    Hypoactive Sexual Desire Disorder Therapeutics
    Dormant ProductsProducts under Development by
    Companies, 2014

11
List of Figures
  • Number of Products under Development for Female
    Hypoactive Sexual Desire Disorder, 2014Late
    Clinical Stage Products (Filed and Phase III),
    2014Mid Clinical Stage Products (Phase II),
    2014Early Clinical Stage Products (Phase I and
    IND Filed), 2014Discovery and Pre-Clinical Stage
    Products, 2014Female Hypoactive Sexual Desire
    Disorder Assessment by Monotherapy
    Products Female Hypoactive Sexual Desire
    Disorder Assessment by Combination
    Products Female Hypoactive Sexual Desire
    Disorder Assessment by Route of
    Administration Female Hypoactive Sexual Desire
    Disorder Assessment by Stage and Route of
    Administration Female Hypoactive Sexual Desire
    Disorder Assessment by Molecule Type Female
    Hypoactive Sexual Desire Disorder Assessment by
    Stage and Molecule Type

12
Related Reports
  • Laboratory Information Management Systems/ LIMS
    Market by Product (COTS Legacy), Delivery Mode
    (On-premise, Hosted, Cloud), Component (Software
    Services), End User Industries (Healthcare,
    CRO, Petrochemical, Oil and Gas, Chemical) -
    Forecast to 2019
  • 2015 Worldwide Nursing Care Facilities
    Industry-Industry Market Report
  • 2015 Worldwide Medical Surgical Hospitals
    Industry-Industry Market Report
  • 2015 Worldwide Home Health Care Services
    Industry-Industry Market Report
  • 2015 Worldwide Offices of Dentists
    Industry-Industry Market Report
  • Ascension Health - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Accretive Health, Inc. (ACHI) - Strategic SWOT
    Analysis Review

13
  • Female Hypoactive Sexual Desire Disorder-Pipeline
    Insights, 2014
  • Published Dec. 2014 60 Pages
  • DelveInsights, Female Hypoactive Sexual Desire
    Disorder-Pipeline Insights, 2014, report provides
    comprehensive insights about pipeline drugs
    across this indication.

  • Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com